Postprandial concentrations and distribution of apo C-III in type 2 diabetic patients. Effect of bezafibrate treatment

This publication has 22 references indexed in Scilit:

• Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates.
  Journal of Clinical Investigation, 1995
• An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3' untranslated region polymorphisms.
  Proceedings of the National Academy of Sciences, 1993
• Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles.
  Journal of Clinical Investigation, 1992
• Hypertriglyceridemia as a Result of Human apo CII Gene Expression in Transgenic Mice
  Science, 1990
• Fibric acids: Effects on lipids and lipoprotein metabolism
  The American Journal of Medicine, 1987
• Effect of bezafibrate on lipoprotein secretion by cultured human hepatocytes
  Atherosclerosis, 1987
• Deoxyribonucleic acid polymorphism in the apolipoprotein A-1-C-III gene cluster. Association with hypertriglyceridemia.
  Journal of Clinical Investigation, 1985
• Apolipoprotein C-II and C-III levels in hyperlipoproteinemia
  Metabolism, 1979
• HYPERTRIGLYCERIDÆMIA ASSOCIATED WITH AN ABNORMAL TRIGLYCERIDE-RICH LIPOPROTEIN CARRYING EXCESS APOLIPOPROTEIN C-III-2
  The Lancet, 1979
• Effect of clofibrate on postheparin plasma triglyceride lipase activities in patients with hypertriglyceridemia
  Metabolism, 1977